Winton Group LTD Palatin Technologies Inc Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.37 - $0.54 $137,319 - $200,412	-371,134 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$0.34 - $0.86 $139,140 - $351,942	-409,236 Reduced 52.44%	371,134 $190,000
Q3 2021 Oct 28, 2021	SELL	$0.44 - $0.63 $48,633 - $69,633	-110,530 Reduced 12.41%	780,370 $346,000
Q2 2021 Aug 10, 2021	SELL	$0.48 - $0.72 $13,894 - $20,841	-28,947 Reduced 3.15%	890,900 $543,000
Q1 2021 Jul 21, 2021	SELL	$0.68 - $1.25 $3,268 - $6,008	-4,807 Reduced 0.52%	919,847 $634,000
Q4 2020 Feb 12, 2021	SELL	$0.38 - $0.78 $269,618 - $553,427	-709,522 Reduced 43.42%	924,654 $625,000
Q3 2020 Oct 30, 2020	SELL	$0.47 - $0.64 $128,877 - $175,492	-274,207 Reduced 14.37%	1,634,176 $773,000
Q2 2020 Aug 05, 2020	BUY	$0.41 - $0.73 $474,514 - $844,866	1,157,352 Added 154.1%	1,908,383 $977,000
Q1 2020 May 11, 2020	BUY	$0.36 - $0.79 $19,964 - $43,810	55,456 Added 7.97%	751,031 $318,000
Q4 2019 Feb 13, 2020	SELL	$0.75 - $0.89 $104,300 - $123,769	-139,067 Reduced 16.66%	695,575 $544,000
Q3 2019 Nov 08, 2019	BUY	$0.78 - $1.09 $651,020 - $909,759	834,642 New	834,642 $759,000

3.02K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $8.27M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.